Raghuram Selvaraju, managing director, Healthcare equity research at MLV & Co, discusses whether AbbVie's acquisition of Pharmacyclics for about $21 billion is a good move.» Read More
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.
GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.
CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.
Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.
Colombian Finance Minister Mauricio Cárdenas Santamaria says resolving the country's drugs issue will help the country post stronger growth.
CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
The hemp industry could become one of the U.S.'s biggest now its industrial use had been legalized, says Doug Fine, author of "Hemp Bound".
Luis Videgaray, finance minister of Mexico, says the U.S. must "share responsibility" for tackling drug cartels.
Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.
Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.
Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."
Almost half of Americans ages 40 to 75 qualify to consider cholesterol-lowering statin drugs under new heart disease prevention guidelines.
Powerful new pain killer Zohydro, is prescribed to help people with chronic pain. Dr. Andrew Kolodny thinks the FDA has put out a drug that will kill people. Dr. Steven Garner, New York Methodist Hospital, thinks the drug will help many people who are suffering with lasting pain.
CNBC's Sheila Dharmarajan discusses the new pain killer Zohydro which contains the same addictive elements as Oxycodone.
While out exploring marijuana's first legal frontier, CNBC took a moment to catch up with one young man who has stayed on the darker side of weed—the illegal side.
From exploding kitchens to super-intense highs, making and smoking marijuana concentrate—aka “dabs”—is getting more attention in the move toward legalization.
Todd Mitchem's company, Open Vape, manufactures a product similar to an e-cigarette. It's a pen that heats a cartridge filled with purified cannabis oil.
West, who lives in an affluent Denver suburb, calls herself "one part Martha Stewart and one part Walter White."